Latest News

Tech encourages HIV prevention among women


 

Access to technology, particularly cellphones, is tied to a higher awareness of pre-exposure prophylaxis (PrEP) in women, according to survey results presented at the Association of Nurses in AIDS Care 2023 Annual Meeting.

Those with limited access to technology, older women, and women who had been incarcerated were also less likely to be aware of their medication options.

Researchers collected responses from 206 women in New York and Philadelphia by computer survey. The women were HIV negative and eligible to receive medication but were not currently taking any.

Most participants were Black (61%) or Hispanic (24%), and the average age of participants was 39 years. Nearly 60% of the group reported they were not aware of PrEP.

Younger women, Hispanic women, women who had not been incarcerated, and women with access to technology were most likely to be aware that they could take medication to prevent HIV.

“Women who utilized their cell phones for activities such as texting, emailing, watching videos, playing games, downloading apps, and accessing social media were more likely to be aware of PrEP,” point out the researchers led by Su Kyung Kim, PhD, WHNP-BC, an assistant professor at Thomas Jefferson University, Philadelphia.

These findings could help direct efforts to increase awareness among women where uptake has remained low, the researchers report. “Mobile technologies, in particular, offer a nimble, customizable, and accessible way to reach this target population and increase awareness of PrEP.”

A version of this article first appeared on Medscape.com.

Recommended Reading

The evolving pulmonary landscape in HIV
MDedge Infectious Disease
Daily statin cuts cardiovascular risk in HIV
MDedge Infectious Disease
Low HIV levels linked to ‘almost zero’ risk of sexual transmission
MDedge Infectious Disease
UNAIDS targets: Progress reported, but ‘HIV is far from over’
MDedge Infectious Disease
Injecting long-acting antiretrovirals into clinic care
MDedge Infectious Disease
Results from halted islatravir antiretroviral trial presented
MDedge Infectious Disease
Rising viral load on dolutegravir? Investigators try fix before switch
MDedge Infectious Disease
OxyContin marketing push still exacting a deadly toll, study says
MDedge Infectious Disease
New recommendation expands antiretroviral guidance for HIV
MDedge Infectious Disease
Primary care clinicians should spearhead HIV prevention
MDedge Infectious Disease